J&J Petitions FDA To Regulate Naming Of Biosimilars

13-01-2014 BioResearch OnlineComments (0)

BiosimilarsJohnson & Johnson

Johnson & Johnson addressed the FDA with a petition requesting that the U.S. administration regulate the labeling of biosimilars; specifically those that bear names reminiscent of their reference product but are not indistinctly the same. According to ...

Read more on BioResearch Online

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top